Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Florence – page 41

820 clinical trials in Florence, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Florence at a glance
820
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

820 trials in Florence

Open in trial search

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study of inhaled BX004 bacteriophage treatment for adults with cystic fibrosis who have chronic Pseudomonas aeruginosa lung infection

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IHMA-2121771-1
  • Sponsor:Biomx Ltd.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Study of zorevunersen to reduce seizures in patients with Dravet syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zorevunersen sodium
  • Sponsor:Stoke Therapeutics Inc.

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Study of baxdrostat compared to placebo to treat adults with primary aldosteronism

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study of BI 765423 given by intravenous infusion for patients with idiopathic pulmonary fibrosis with or without standard treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 765423
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hidradenitis

Not recruiting

Study of ruxolitinib cream for treating hidradenitis suppurativa in adult patients

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Migraine

Not recruiting

Study of Rimegepant for Prevention of Menstrual Migraine in Women Aged 18-45 Years

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Florence

What the registry says about research in the country

01 Neurological Disorders

Clinical research focusing on innovative treatments for frontotemporal dementia, multiple sclerosis, and Dravet syndrome. Studies evaluate novel therapeutic approaches including DNL593 for FTD and frexalimab for relapsing MS.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Seizure Control in Dravet Syndrome

Emphasis on safety assessment and long-term efficacy monitoring.

02 Oncology Research

Comprehensive studies targeting various cancer types including colorectal cancer, breast cancer, and lung cancer. Trials explore combination therapies and novel treatment approaches.

  • Metastatic Colorectal Cancer Treatment
  • Advanced Breast Cancer Therapies
  • NSCLC Post-Surgery Care

Focus on targeted therapies and personalized treatment approaches.

03 Autoimmune Conditions

Investigating treatments for psoriatic arthritis, Sjögren's syndrome, and systemic sclerosis. Research includes evaluation of new biologics and targeted therapies.

  • Psoriatic Arthritis Management
  • Sjögren's Syndrome Treatment
  • Systemic Sclerosis Interventions

Studies aim to improve quality of life and disease management.

04 Respiratory Medicine

Studies examining treatments for COPD and respiratory infections, including evaluation of tezepelumab for moderate to severe COPD and prevention of RSV in infants.

  • COPD Exacerbation Management
  • RSV Prevention in Infants
  • Respiratory Disease Therapies

Focus on improving respiratory outcomes and prevention strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.